Thursday, November 5, 2026
ExploreSearch
Via News
MarketIndexes

NYSE FANG Jumps By 4% In The Last 5 Sessions

ViaNews Editorial Team

September 17, 2024

NYSE FANG Jumps By 4% In The Last 5 Sessions

(VIANEWS) - NYSE FANG (NYFANG) has been up by 4.76% for the last 5 sessions. At 10:10 EST on Tuesday, 17 September, NYSE FANG (NYFANG) is $11,231.75.

Regarding NYSE FANG's yearly highs and lows, it's 60.13% up from its 52-week low and 8.54% down from its 52-week high.

Volatility

NYSE FANG's last week, last month's, and last quarter's current intraday variation average was a positive 1.56%, a negative 0.01%, and a positive 1.56%, respectively.

NYSE FANG's highest amplitude of average volatility was 1.56% (last week), 1.53% (last month), and 1.56% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYSE FANG's is considered to be oversold (<=20).

News about

  • According to FXStreet on Monday, 16 September, "The index of 30 stocks is up 0.3% at lunchtime in New York, while the NASDAQ has moved 1% lower and the S&P 500 is off 0.2%. "

More news about NYSE FANG (NYFANG).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesNYFANGNYSE FANGPrice UpINDICES Price UpIndex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com